Ohr Pharmaceutical Inc (Ohr) is a biotechnology company. The Company focuses on the development of its two products, OHR/AVR118 for the treatment of cancer cachexia (multi-symptom wasting disorder), and Squalamine for the treatment of the wet form of age-related macular degeneration using an eye drop formulation. As of September 30, 2012, the Company is engaged in the clinical testing of OHR/AVR118 and the Squalamine eye drop program for the treatment of wet-AMD. On September 24, 2012, the Company announced the initiation of a multi center, randomized, placebo controlled Phase II trial to evaluate the efficacy and safety of Squalamine eye drops for the treatment of the wet form of age-related macular degeneration. In September 2012, the Company commenced a clinical study, named OHR-002.